[go: up one dir, main page]

MX2012008147A - Derivados de pirrazolopiridina. - Google Patents

Derivados de pirrazolopiridina.

Info

Publication number
MX2012008147A
MX2012008147A MX2012008147A MX2012008147A MX2012008147A MX 2012008147 A MX2012008147 A MX 2012008147A MX 2012008147 A MX2012008147 A MX 2012008147A MX 2012008147 A MX2012008147 A MX 2012008147A MX 2012008147 A MX2012008147 A MX 2012008147A
Authority
MX
Mexico
Prior art keywords
sub
lower alkyl
halogen
substituted
hydrogen
Prior art date
Application number
MX2012008147A
Other languages
English (en)
Inventor
Heinz Stadler
Hasane Ratni
Matthias Nettekoven
Philippe Jablonski
Angelique Patiny-Adam
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012008147A publication Critical patent/MX2012008147A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención, se relaciona con un compuesto de la Fórmula (I) en donde R1 es hidrógeno, alquilo inferior, alquilo inferior substituido por halógeno, bencilo, -C(O)-alquilo inferior, -C(O)-CH2-alcoxi inferior, C-(O)cicloalquil-C3-6 -(CH2)o-C(O)-NR,R´, -(CH2)0S(O)2-alquilo inferior o -S(O)2-NR,R´; o es 0 o 1; R, R´ son independientemente uno de otro hidrógeno o alquilo inferior, o pueden formar junto con el átomo N al cual están unidos 5 o 6 miembros del anillo heterocicloalquilo; R2 es hidrógeno o alquilo inferior; R3 es halógeno, alcoxi inferior, alquilo inferior substituido por halógeno o alcoxi inferior substituido por halógeno; y pueden ser iguales o diferentes en caso de que n sea 2; n es 1 o 2; Ar es fenilo opcionalmente substituido por uno o dos sustituyentes seleccionados del alquilo inferior, halógeno, alcoxi inferior, alquilo inferior substituido por hidroxi o ciano, o es un grupo heteroarilo con cinco o seis miembros, seleccionado de tiofenilo o piridinilo que son substituidos opcionalmente por alquilo o halógeno inferior; o a una sal de adición de ácido farmacéuticamente activa. Se ha encontrado asombrosamente que los compuestos de la fórmula 1 muestran una alta afinidad simultáneamente a ambos los receptores NK1 y NK3 (antagonistas de los receptores NK1/NK3 duales), útiles en el tratamiento de esquizofrenia.
MX2012008147A 2010-04-20 2011-04-15 Derivados de pirrazolopiridina. MX2012008147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160481 2010-04-20
PCT/EP2011/055971 WO2011131571A1 (en) 2010-04-20 2011-04-15 Pyrrazolopyridine derivatives

Publications (1)

Publication Number Publication Date
MX2012008147A true MX2012008147A (es) 2012-08-03

Family

ID=43923714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008147A MX2012008147A (es) 2010-04-20 2011-04-15 Derivados de pirrazolopiridina.

Country Status (11)

Country Link
US (1) US8487102B2 (es)
EP (1) EP2560974B1 (es)
JP (1) JP5592992B2 (es)
KR (1) KR101484831B1 (es)
CN (1) CN102858775B (es)
BR (1) BR112012026458A2 (es)
CA (1) CA2786837A1 (es)
ES (1) ES2562983T3 (es)
MX (1) MX2012008147A (es)
RU (1) RU2561276C2 (es)
WO (1) WO2011131571A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
WO2016184829A1 (en) 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
SG11202008226YA (en) 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2024220539A1 (en) 2023-04-18 2024-10-24 Kallyope, Inc. Nk3 modulators and uses thereof
WO2024220541A1 (en) * 2023-04-18 2024-10-24 Kallyope, Inc. Nk3 modulators and uses thereof
WO2024220543A1 (en) * 2023-04-18 2024-10-24 Kallyope, Inc. Nk3 modulators and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE278687T1 (de) 1993-12-29 2004-10-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als therapeutische mittel
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE69531458T2 (de) * 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1319001A1 (en) * 2000-09-22 2003-06-18 Smithkline Beecham Plc Pyrazolopyridines and pyrazolopyridazines as antidiabetics
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
AU2002222293A1 (en) * 2000-12-19 2002-07-01 Smithkline Beecham P.L.C. Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
PL214231B1 (pl) * 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
JP2006513159A (ja) * 2002-11-01 2006-04-20 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
RU2348633C2 (ru) * 2002-12-23 2009-03-10 Глаксо Груп Лимитед ПИРАЗОЛО[3,4-b]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
AU2004253267B2 (en) 2003-07-03 2008-12-04 F. Hoffmann-La Roche Ag Dual NK1/NK3 antagonists for treating schizophrenia
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2007036734A1 (en) * 2005-09-29 2007-04-05 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)

Also Published As

Publication number Publication date
KR20130027513A (ko) 2013-03-15
JP5592992B2 (ja) 2014-09-17
CA2786837A1 (en) 2011-10-27
EP2560974B1 (en) 2016-01-27
WO2011131571A1 (en) 2011-10-27
US8487102B2 (en) 2013-07-16
RU2561276C2 (ru) 2015-08-27
ES2562983T3 (es) 2016-03-09
HK1174625A1 (en) 2013-06-14
CN102858775B (zh) 2015-04-01
KR101484831B1 (ko) 2015-01-20
BR112012026458A2 (pt) 2016-08-09
RU2012146874A (ru) 2014-05-27
JP2013530131A (ja) 2013-07-25
US20110257402A1 (en) 2011-10-20
CN102858775A (zh) 2013-01-02
EP2560974A1 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
MX2012008147A (es) Derivados de pirrazolopiridina.
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
JO2871B1 (en) Perol compounds
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
UA109525C2 (xx) Алкіламідна сполука і її застосування
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR088235A1 (es) Derivados de pirazoloquinolina
WO2009156861A3 (en) Substituted pyrimidone derivatives
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
WO2008051533A3 (en) Benzimidazole compounds
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
WO2008136444A1 (ja) 縮合複素環誘導体
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
EP1867331A4 (en) TRIAZOLE DERIVATIVE AND USE THEREOF
MX2011012057A (es) Derivados de ciclopenta [c] pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su uso en terapéutica.
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
MX2009010727A (es) Heterociclos como antagonistas de orexina.
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration